Salvage lymphadenectomy in patients with recurrent prostate cancer after radical prostatectomy A.O. Vasil’ev, A.V. Govorov, D.Yu. Pushkar’
https://doi.org/10.17650/1726-9776-2017-13-2-174-188
Abstract
A separate group of patients who underwent radical prostatectomy, make patients with isolated recurrence of cancer in the lymph nodes, limited by regional and / or retroperitoneal lymph nodes. Alternatively, treatment of this patient group can be used open or laparoscopic lymphadenectomy (robot-assisted). The analysis of literature indicate an increase in disease-free survival of these patients during lymphadenectomy. Imaging techniques such as multiparametric magnetic resonance imaging and positron emission tomography, allow more accurately identify lymph nodes in patients with biochemical recurrence of prostate cancer after radical prostatectomy.
About the Authors
A. O. Vasil’ev
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Competing Interests: отсутствует конфликт интересов
Russian Federation
Urology Department
Build. 1, 20 Delegatskaya St., Moscow 127473
Competing Interests: отсутствует конфликт интересов
A. V. Govorov
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Urology Department
Competing Interests: отсутствует конфликт интересов
Russian Federation
Urology Department
Competing Interests: отсутствует конфликт интересов
D. Yu. Pushkar’
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Urology Department
Competing Interests: Отсутствует конфликт интересов
Russian Federation
Urology Department
Competing Interests: Отсутствует конфликт интересов
References
1. Abdollah F., Briganti A., Montorsi F. et al. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol 2015;67(5):839–49. DOI: 10.1016/j.eururo.2014.03.019. PMID: 24698524.
2. Mottet N., Bellmunt J., Briers E. et al. Netherlands: European Association of Urology, 2017. 146 р.
3. Giovacchini G., Picchio M., GraciaParra R. et al. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen deprivation therapy. J Nucl Med 2014;55(2): 233–41. DOI: 10.2967/jnumed.113.123380. PMID: 24408897.
4. Suardi N., Porter C.R., Reuther A.M. et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008;112(6):1254–63. DOI: 10.1002/cncr.23293. PMID: 18286530.
5. de Jong I.J., Pruim P., Elsinga W. et al. C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44(1):32–9. PMID: 12814672.
6. Giovacchini G., Picchio M., Briganti A. et al. 11C-choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 2010;184(3):938–43. DOI: 10.1016/j.juro.2010.04.084. PMID: 20643445.
7. Krause B.J., Souvatzoglou M., Tuncel M. et al. The detection rate of 11C-cholinePET/CT depends on the serum PSAvalue in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35(1):18–23. DOI: 10.1007/s00259-007-0581-4. PMID: 17891394.
8. Heesakkers R.A., Hovels A.M., Jager G.J. et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008;9(9):850–6. DOI: 10.1016/S1470-2045(08)70203-1. PMID: 18708295.
9. Lecouvet F.E., El Mouedden J., Collette L. et al. Can whole-body magnetic resonance imaging with diffusionweighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012;62(1):68–75. DOI: 10.1016/j.eururo.2012.02.020. PMID: 22366187.
10. Harisinghani M.G., Barentsz J., Hahn P.F. et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. New Engl J Med 2003;348(25):2491–9. DOI: 10.1056/NEJMoa022749. PMID: 12815134.
11. Wang L., Hricak H., Kattan M.W. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 2006;186(3):743–8. DOI: 10.2214/AJR.04.1682. PMID: 16498101.
12. Schilling D., Schlemmer H.P., Wagner P.H. et al. Histological verification of 11Ccholine-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008;102(4):446–51. DOI: 10.1111/j.1464-410X.2008.07592.x. PMID: 18410442.
13. Winter A., Uphoff J., Henke R.P., Wawroschek F. First results of 11Ccholine PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int 2010;84(4):418–23. PMID: 20299773. DOI: 10.1159/000296298.
14. Rinnab L., Mottaghy F.M., Simon J. 11C-Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer: preliminary results of a prospective study. Urol Int 2008;81(2): 191–7. DOI: 10.1159/000144059. PMID: 18758218.
15. Castellucci P., Fuccio C., Rubello D. et al. Is there a role for 11C-choline PET/ CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase < 1.5 ng/ml? Eur J Nucl Med Mol Imaging 2011;38(1):55–63. DOI: 10.1007/s00259-010-1604-0. PMID: 20848281.
16. Mamede M., Ceci F., Castellucci P. et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level < 0.5 ng/ mL. Clin Nucl Med 2013;38(9):e342–5. DOI: 10.1097/RLU.0b013e31829af913. PMID: 23797218.
17. Tilki D., Reich O., Graser A. et al. 18FFluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 2013;63(5):792–6. DOI: 10.1016/j.eururo.2012.08.003. PMID: 22902037.
18. Rigatti P., Suardi N., Briganti A. et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by 11C-choline positron emission tomography/computed tomography. Eur Urol 2011;60:935–43. DOI: 10.1016/j.eururo.2011.07.060.
19. Jilg C.A., Rischke H.C., Reske S.N. et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012;188(6):2190–7. DOI: 10.1016/j.juro.2012.08.041. PMID: 23083862.
20. Suardi N., Karnes J., Joniau S. et al. Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases. J Urol 2013;189:317–8.
21. Suardi N., Gandaglia G., Gallina A. et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 2015;67(2):299–309. DOI: 10.1016/j.eururo.2014.02.011. PMID: 24571959.
22. Coelho R.F., Palmer K.J., Moniz R.R. et al. Early complication rates in a singlesurgeon series of 2500 robotic-assisted radical prostatectomies: report applying a standardized grading system. Eur Urol 2010;57(6):945–52. DOI: 10.1016/j.eururo.2010.02.001. PMID: 20181424.
Review
For citations:
Vasil’ev A.O., Govorov A.V., Pushkar’ D.Yu. Salvage lymphadenectomy in patients with recurrent prostate cancer after radical prostatectomy A.O. Vasil’ev, A.V. Govorov, D.Yu. Pushkar’. Cancer Urology. 2017;13(2):67-73. (In Russ.) https://doi.org/10.17650/1726-9776-2017-13-2-174-188
Views:
1487
Email this article 